Estrogen receptor-α phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression

Cancer Research

Volumn 66, Issue 20, 2006, Pages 10162-10170

  Weitsman, Gregory E ^a   Li, Lin ^a   Skliris, George P ^a   Davie, James R ^a   Ung, Kanyarat ^a   Niu, Yulian ^a   Curtis Snell, Linda ^a   Tomes, Ladislav ^a   Watson, Peter H ^a   Murphy, Leigh C ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR ALPHA; I KAPPA B KINASE ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P300; PURINE DERIVATIVE; ROSCOVITINE; SERINE; STEROID RECEPTOR COACTIVATOR 3; UO 126;

ARTICLE; BREAST CANCER; CANCER CELL; CELL LEVEL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; GENE CONTROL; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CYCLIN-DEPENDENT KINASES; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); RECEPTOR, ERBB-2; TRANSCRIPTION, GENETIC;

EID: 33750552134     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4111     Document Type: Article

References (38)

1. Lannigan D. Estrogen receptor phosphorylation. Steroids 2003;68:1-9.
2. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen activated protein kinase. Science 1995;270:1491-4.
3. Chen D, Washbrook E, Sarwar N, et al. Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 2002;21:4921-31.
4. Park K, Krishnan V, O'Malley B, Yamamoto Y, Gaynor R. Formation of an IKKα-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mo; Cell 2005;18:71-82.
5. Schiff R, Massarweh S. Shou J, Bharwani L, Mohsin S, Osborne C. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331-6S.
6. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001;61:8452-8.
7. Pietras R, Arboleda J, Reese D, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone independent growth in human breast cancer cells. Oncogene 1995;10:2435-46.
8. Knowlden J, Hutcheson I, Jones H, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003;144:1032-44.
9. Murphy LC, Cherlet T, Adeyinka A, Niu Y, Snell L, Watson P. Phospho-serine-118 estrogen receptor-α detection in human breast tumors in vivo. Clin Cancer Res 2004;10:1354-9.
10. Murphy L, Niu Y, Snell L, Watson P. Phospho-serine-118 estrogen receptor-α expression in primary human breast tumors in vivo is associated with better disease outcome in women treated with tamoxifen. Clin Cancer Res 2004;10:5902-6.
11. Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000;19:3460-9.
12. Ravid A, Koren R, Rotem C, Garach-Jehoshua O, Glaser T, Liberman U. 1,25-Dihydroxyvitamin D3 increases the cellular content of the calcium-activated neutral protease mu-calpain in renal cell carcinoma. Endocrinology 1994;135:2822-5.
13. Spencer V, Sun J, Li L, Davie J. Chromatm immunoprecipitation: a tool for studying histone acetylation and transcription factor binding. Methods 2003;31:67-75.
14. Wells J, Boyd K, Fry C, Bartley S, Farnham P. Target gene specificity of E2F and pocket protein family members in living cells. Mol Cell Biol 2000;20:5797-807.
15. Espino P, Li L, He S, Yu J, Davie J. Chromatin modification of the trefoil factor 1 gene in human breast cancer cells by the Ras/mitogen-activated protein kinase pathway. Cancer Res 2006;66:4610-6.
16. Berry M, Nunez A, Chambon P. Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci U S A 1989;86:1218-22.
17. Berry A, Scott H, Kudoh J, et al. Refined localization of autosomal recessive nonsyndromic deafness DFNB10 locus using 34 novel microsatellite markers, genomic structure, and exclusion of six known genes in the region. Genomics 2000;68:22-9.
18. Petz L, Ziegler Y, Loven M, Nardulli A. Estrogen receptor a and activating protein-1 mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells. Endocrinology 2002;143:4583-91.
19. Petz L, Ziegler Y, Schultz J, Kim H, Kemper J, Nardulli A. Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites. J Steroid Biochem Mol Biol 2004;88:113-22.
20. Dubik D, Shiu KP. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 1992;7:1587-94.
21. 1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol 2004;24:7260-74.
22. Watson P, Snell L, Parisien M. The NCIC-Manitoba Breast Tumor Bank: a resource for applied cancer research. CMAJ 1996;155:281-3.
23. Petz L, Nardulli A. Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Mol Endocrinol 2000;14:972-85.
24. Chen D, Washbrook E, Sarwar N, et al. Activation of estrogen receptor α by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell Biol 2000;6:127-37.
25. Pierce J, Schoenleber R, Jesmok G, et al. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997;272:21096-103.
26. Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 2002;190:160-9.
27. Joel P, Traish A, Lannigan D. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem 1998;273:13317-23.
28. Shou J, Massarweh S, Osborne C, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
29. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 1994;269:4458-66.
30. Endoh H, Maruyama K, Masuhiro Y, et al. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor α. Mol Cell Biol 1999;19:5363-72.
31. Archer T, Cordingley M, Wolford R, Hager G. Transcription factor access is mediated by accurately positioned nucleosomes on the mouse mammary tumor virus promoter. Mol Cell Biol 1991;11:688-98.
32. Callige M, Kieffer I, Richard-Foy H. CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor α by the proteasome. Mol Cell Biochem 2005;25:4349-58.
33. Masuhiro Y, Mezaki Y, Sakari M, et al. Splicing potentiation by growth factor signals via estrogen receptor phosphorylation. Proc Natl Acad Sci U S A 2005;102:8126-31.
34. Metivier R, Penot G, Hubner M, et al. Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003;115:751-63.
35. Adeyinka A, Niu Y, Cherlet T, Snell L, Watson P, Murphy L. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 2002;8:1747-53.
36. Gee J, Robertson J, Ellis I, Nicholson R. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001;95:247-54.
37. Mora JFd, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000;20:5041-7.
38. Anzick S, Kononen J, Walker R, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-8.